SEC Tracker
Get the app

MaxCyte MXCT

MaxCyte Q1 FY26: revenue $9.7M, down 7%; diluted EPS −$0.04

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers MaxCyte reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$9.7M−7% from $10.4M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$4.8MAgainst −$10.3M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.04Against −$0.10 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$14.6M−38% from $23.4M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$8.2MAgainst −$14.4M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when MaxCyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. NRC Health NRC public float $195M, Jun 30, 2025
  2. Absci ABSI public float $304M, Jun 30, 2025
  3. OmniAb OABI public float $145M, Jun 30, 2025
  4. Neogenomics NEO public float $680M, Jun 30, 2025
  5. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old